Envestnet Asset Management Inc. Cuts Stock Position in Edwards Lifesciences Corporation $EW

Envestnet Asset Management Inc. lowered its stake in shares of Edwards Lifesciences Corporation (NYSE:EW) by 23.1% in the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 261,587 shares of the medical research company’s stock after selling 78,709 shares during the period. Envestnet Asset Management Inc.’s holdings in Edwards Lifesciences were worth $20,344,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of EW. Brighton Jones LLC purchased a new stake in shares of Edwards Lifesciences during the fourth quarter worth approximately $266,000. CWM LLC boosted its stake in Edwards Lifesciences by 24.1% during the 2nd quarter. CWM LLC now owns 40,851 shares of the medical research company’s stock worth $3,195,000 after purchasing an additional 7,935 shares during the last quarter. MGO One Seven LLC grew its holdings in shares of Edwards Lifesciences by 9.1% during the second quarter. MGO One Seven LLC now owns 7,266 shares of the medical research company’s stock worth $568,000 after buying an additional 604 shares in the last quarter. Ritholtz Wealth Management acquired a new stake in shares of Edwards Lifesciences in the second quarter valued at about $203,000. Finally, Turtle Creek Wealth Advisors LLC purchased a new position in shares of Edwards Lifesciences in the second quarter worth about $216,000. 79.46% of the stock is owned by hedge funds and other institutional investors.

Insider Transactions at Edwards Lifesciences

In related news, VP Donald E. Bobo, Jr. sold 11,340 shares of the business’s stock in a transaction that occurred on Tuesday, January 6th. The stock was sold at an average price of $85.66, for a total transaction of $971,384.40. Following the completion of the sale, the vice president owned 31,870 shares in the company, valued at $2,729,984.20. The trade was a 26.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Daniel J. Lippis sold 1,019 shares of the stock in a transaction that occurred on Friday, January 9th. The shares were sold at an average price of $85.70, for a total transaction of $87,328.30. Following the completion of the transaction, the vice president owned 22,002 shares in the company, valued at $1,885,571.40. This represents a 4.43% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 43,804 shares of company stock valued at $3,699,082. Corporate insiders own 1.29% of the company’s stock.

Analyst Ratings Changes

EW has been the topic of a number of recent research reports. Stifel Nicolaus set a $110.00 price objective on Edwards Lifesciences and gave the stock a “buy” rating in a research note on Tuesday, January 20th. National Bank Financial set a $92.00 price target on shares of Edwards Lifesciences in a research report on Friday, October 31st. Piper Sandler reissued an “overweight” rating and issued a $100.00 price objective (up previously from $98.00) on shares of Edwards Lifesciences in a report on Wednesday. Barclays restated an “overweight” rating and set a $104.00 price objective (up from $103.00) on shares of Edwards Lifesciences in a research report on Monday, January 12th. Finally, Mizuho increased their price target on shares of Edwards Lifesciences from $90.00 to $100.00 and gave the company an “outperform” rating in a research note on Friday, October 31st. Three analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and nine have given a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $96.14.

Edwards Lifesciences Trading Down 0.8%

Shares of NYSE:EW opened at $75.80 on Friday. Edwards Lifesciences Corporation has a 52 week low of $65.94 and a 52 week high of $87.89. The company’s 50 day moving average is $83.34 and its two-hundred day moving average is $81.08. The company has a market cap of $43.99 billion, a PE ratio of 41.42, a P/E/G ratio of 1.98 and a beta of 0.94. The company has a current ratio of 4.00, a quick ratio of 3.29 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last issued its earnings results on Tuesday, February 10th. The medical research company reported $0.58 EPS for the quarter, missing analysts’ consensus estimates of $0.62 by ($0.04). The firm had revenue of $1.57 billion for the quarter, compared to analyst estimates of $1.54 billion. Edwards Lifesciences had a return on equity of 14.50% and a net margin of 17.69%.The business’s revenue for the quarter was up 13.3% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.59 EPS. Edwards Lifesciences has set its Q1 2026 guidance at 0.700-0.760 EPS. Equities analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.